CPRX CATALYST PHARMACEUTICALS, INC. Insider Trading

Chief Compliance Officer Brian Elsbernd sells 40,000 CPRX shares at $22.70, retaining 231,039 shares; stock up 9.0% in 30 days.

Elsbernd sold 40,000 shares (40.0K shares) at $22.70 on 2025-11-12, representing a -14.8% reduction from his 271,039 pre-transaction holdings. At the time of sale, CPRX had gained 9.0% over the prior 30 days and 14.6% over 90 days, contextualizing the sale against a period of upward price momentum. His same-ticker trade history at CPRX shows 5 prior sells, with measurable 90-day outcomes on 2 trades: both resulted in positive 90-day returns (+7.4% and +8.8%), indicating that his prior CPRX sales were not well-timed (the stock rose after he sold). The company's latest quarter generated $148.4M in revenue with $52.8M net income and 23.5% annual revenue growth, accompanied by a P/E of 13.10, suggesting moderate valuation relative to profitability. The discretionary nature and quantum of this sale warrant monitoring against any forward signals regarding operational or market outlook.

Chief Compliance Officer Brian Elsbernd sells 30,000 CPRX shares at $20.30; stock down 25.0% from 52-week high.

Brian Elsbernd, Chief Compliance/Legal Officer, sold 30,000 shares (10.0% of pre-transaction holdings) at $20.30 on 2025-09-08, following two consecutive sales on 2025-09-04 and 2025-09-03. The stock currently trades at $19.74, which is 25.0% below its 52-week high of $26.31 and down 18.7% over the past 90 days. His prior sales at CPRX have not demonstrated prescient timing: 2 measurable outcomes from March 2025 show positive 90-day returns (+7.4% and +8.8%), indicating the stock rose after those sales. Against his cross-ticker track record, his 90-day well-timed rate stands at 0.00%, and average 90-day returns after his open-market sells have been +8.2%. The company's fundamentals remain solid—$146.6M quarterly revenue, $52.1M net income, 23.5% annual revenue growth, and a P/E of 11.61—indicating no obvious operational stress. The concentration of three sales within five days warrants monitoring, though the lack of measurable outcomes for the two most recent sales limits pattern interpretation.

Chief Compliance Officer Elsbernd sold 50,000 shares (50.0K shares) for $987,200.00 across two trades; stock down 21.6% in 90 days.

Brian Elsbernd, Chief Compliance/Legal Officer at Catalyst Pharmaceuticals, executed 2 separate sales totaling 50,000 shares (50.0K shares) for $987,200.00 on 2025-09-03 and 2025-09-04, reducing his holdings by 21.0% from 238,564 shares to 188,564 shares. The stock has declined 21.6% over the 90-day period and 6.9% over 30 days, trading 22.9% below its 52-week high of $26.31. The company shows solid fundamentals with $146.6M in latest quarterly revenue, $52.1M net income, 23.5% annual revenue growth, and an 11.94 P/E ratio. While his prior 2 sales at this ticker generated positive 90-day returns (averaging +8.1%), his cross-ticker track record shows 0.00% well-timed rate on sells, indicating his historical sales have not generally preceded further declines—a pattern that differs from the current post-sale weakness at this specific company.

COO/Scientific Officer Miller sells 115,000 CPRX shares at $20.28; stock down 22.5% from 52-week high.

Miller Steve, Chief Operating and Scientific Officer of Catalyst Pharmaceuticals, sold 115,000 shares (9.8% reduction from 1,174,663 pre-transaction holdings) at $20.28 on 2025-08-26, generating $2.3M in proceeds. At current price of $20.38, the stock is -22.5% from its 52-week high of $26.31 and down -18.4% over the past 90 days. Across his prior 4 trades at CPRX specifically, only 1 of 4 sells registered a negative 90-day return (well-timed for sells), suggesting modest timing precision at this ticker. The company shows healthy fundamentals—$146.6M quarterly revenue, $52.1M net income, and 23.5% annual revenue growth with an 11.99 P/E—which contrasts with recent stock weakness and provides context for evaluating whether this sale represents conviction-driven exit or portfolio rebalancing against a broader market correction.

Director McEnany sells 200,000 CPRX shares for $5.2M in two tranches; stock near 52-week high at $26.31.

Patrick J. McEnany, a director of Catalyst Pharmaceuticals, executed 2 separate sales totaling 200,000 shares for $5,217,338.42 between June 6 and June 9, 2025, at a blended average price of $26.09 per share. The current price of $26.31 is at the 52-week high, and the stock has gained 12.6% over the last 30 days and 24.1% over 90 days, indicating a period of strong upward momentum. McEnany retains 4,281,702 shares post-transaction, reducing his holdings by 4.5%. His prior sales at this ticker (5 trades in late November 2024) showed mixed timing outcomes, with 2 of 5 being well-timed at the 90-day mark; however, his cross-ticker track record shows a 57.14% well-timed rate across 7 prior sells with an average 90-day return of +1.8%, suggesting his sells have historically underperformed (selling before upside rather than before declines). The fundamentals show strong performance with $141.4M in latest-quarter revenue, $56.7M net income, and 23.5% annual revenue growth at a P/E of 16.24.

CPRX CEO Daly sells 70,000 shares at $24.86 for $1.7M; retains 199,764 shares post-sale

Richard J Daly, President and CEO of Catalyst Pharmaceuticals, sold 70,000 shares (25.9% of his pre-transaction holdings) at $24.86 on 2025-05-30 for $1,740,200.00. The company's fundamentals remain robust with Revenue of $141,421,000.00 in the latest quarter, net income of $56,737,000.00, a P/E of 15.38, and annual revenue growth of +23.5%. The sale occurs near the 52-week high ($25.74), with the stock currently trading at $24.91. Despite the significant share reduction, the CEO retains 199,764 shares, maintaining substantial residual ownership and alignment with shareholders.

Chief Med. & Reg. Officer sells 244,000 shares (78% of holdings) for $5.8M at $23.67–$23.68 avg

Gary Ingenito executed 2 separate sales totaling 244,000 shares for $5,775,720.00, reducing his CPRX holdings from 312,873 shares to 68,873 shares — a 78.0% reduction in stake. The sales occurred at $23.68 on 2025-05-13 and $23.63 on 2025-05-14, near the stock's 52-week high of $25.74 (current price $23.78 is 7.6% below peak). At the same-ticker level, Ingenito's 4 prior CPRX sells show mixed timing: two recent sales (2025-03-05 and 2025-03-06) posted 30-day gains of +4.4% and +6.5%, while his 2024 sales displayed an 0-of-2 well-timed rate at the 90-day horizon, suggesting stock strength after his prior exits. Against favorable fundamentals (P/E 14.68, +23.5% annual revenue growth, $56.7M net income), the substantial reduction in executive stake warrants investor attention to underlying conviction and capital allocation timing.

CPRX CMO Gary Ingenito sold 225,000 shares (76.6% reduction) for $4,894,609.68 across two trades at $22.09–$21.67 on Mar 5–6, 2025.

Gary Ingenito, Chief Medical and Regulatory Officer of Catalyst Pharmaceuticals, executed two separate sales on March 5–6, 2025, totaling 225,000 shares (225.0K shares) for $4,894,609.68, reducing his holdings from 293,873 shares to 68,873 shares—a 76.6% net reduction. The blended average sale price of $21.75 is slightly below the current price of $21.96, and the stock is trading 8.4% below its 52-week high of $23.96. At the same-ticker level, Ingenito's two prior sales at CPRX (August 2024 and June 2024) showed average 90-day returns of +25.5% and +22.2% respectively—both poorly-timed exits, as the stock continued to rise after he sold. The company's fundamentals remain solid (P/E 11.32, +23.5% annual revenue growth, $128.7M quarterly revenue, $43.9M net income), suggesting this large reduction is not driven by deterioration in the underlying business.

CCO Brian Elsbernd sells 62,975 CPRX shares across 2 transactions for $1,446,932.75; retains 188,564 shares post-sale

Brian Elsbernd, Chief Compliance/Legal Officer at Catalyst Pharmaceuticals, executed 2 separate sales totaling 62,975 shares for $1,446,932.75 on 2025-03-03 at blended average price $22.98, reducing his holdings by 25.0% from 251,539 to 188,564 shares. The transactions occurred near the stock's 52-week high ($23.96), with current price at $21.89, placing the execution 8.6% below the year's peak. The company's fundamentals show strong momentum: latest quarterly revenue of $128,695,000.00, net income of $43,884,000.00, and annual revenue growth of +23.5%, alongside a reasonable valuation (P/E 11.28). The magnitude and timing of this sale by a senior legal and compliance officer merit monitoring, particularly given the company's solid financial trajectory and recent strength in stock price.

COO Steve Miller sells 50.0K CPRX shares at $21.93; stock now -8.2% from 52-week high amid 85.9% revenue growth.

Miller sold 50,000 shares (6.8% of his pre-transaction holdings) on 2024-12-10 at $21.93, reducing his stake from 737.0K to 687.0K shares. The company demonstrates strong fundamentals with $128.7M revenue in the latest quarter and annual revenue growth of +85.9%, combined with net income of $43.9M and a reasonable P/E of 18.31. However, the stock has declined 6.3% over the past 30 days and sits -8.2% below its 52-week high of $23.93, suggesting a pullback from recent peaks. Notably, Miller's prior three sales at CPRX all resulted in positive 90-day returns (ranging 1.1% to 3.0%), meaning the stock rose after each sale—a pattern of consistently poorly-timed exits that does not suggest prescient bearish conviction on this occasion either.